Zentalis Pharmaceuticals (NASDAQ:ZNTL) Upgraded to "Hold" at Wall Street Zen

Key Points

• Zentalis Pharmaceuticals was upgraded from a "strong sell" to a "hold" rating by Wall Street Zen, signaling a shift in analysts' outlook on the stock.
• The company's current average rating is "Hold" with a consensus price target of $8.20, while recent analyst reports have set price objectives ranging from $4.00 to $10.00.
• Zentalis Pharmaceuticals recently reported earnings per share of ($0.37), surpassing analysts' expectations of ($0.56).

Wall Street Zen upgraded shares of Zentalis Pharmaceuticals (NASDAQ:ZNTL - Free Report) from a strong sell rating to a hold rating in a research note published on Saturday.

A number of other equities analysts have also recently issued reports on the company. Wedbush reiterated a "neutral" rating and set a $4.00 target price on shares of Zentalis Pharmaceuticals in a report on Thursday, May 15th. Wells Fargo & Company lowered their target price on Zentalis Pharmaceuticals from $6.00 to $5.00 and set an "equal weight" rating for the company in a report on Thursday, August 7th. Finally, HC Wainwright restated a "buy" rating and issued a $10.00 price objective on shares of Zentalis Pharmaceuticals in a report on Thursday, May 15th. Four research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $8.20.

Zentalis Pharmaceuticals Price Performance

ZNTL stock traded up $0.09 during trading hours on Friday, reaching $1.50. 282,266 shares of the stock were exchanged, compared to its average volume of 1,235,663. The firm's 50-day moving average is $1.38 and its 200-day moving average is $1.54. The company has a market cap of $107.85 million, a price-to-earnings ratio of -0.66 and a beta of 1.71. Zentalis Pharmaceuticals has a 12 month low of $1.01 and a 12 month high of $5.44.

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last released its earnings results on Wednesday, August 6th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.56) by $0.19. As a group, equities research analysts forecast that Zentalis Pharmaceuticals will post -2.42 earnings per share for the current year.

Hedge Funds Weigh In On Zentalis Pharmaceuticals

Several hedge funds have recently modified their holdings of the stock. Raymond James Financial Inc. bought a new position in Zentalis Pharmaceuticals during the fourth quarter worth about $68,000. Sei Investments Co. bought a new position in Zentalis Pharmaceuticals during the fourth quarter worth about $107,000. Prudential Financial Inc. bought a new position in Zentalis Pharmaceuticals during the fourth quarter worth about $39,000. JPMorgan Chase & Co. grew its holdings in Zentalis Pharmaceuticals by 75.7% during the fourth quarter. JPMorgan Chase & Co. now owns 859,710 shares of the company's stock worth $2,605,000 after purchasing an additional 370,511 shares during the period. Finally, Franklin Resources Inc. bought a new position in Zentalis Pharmaceuticals during the fourth quarter worth about $323,000.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.